Skip to main content
logo
Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
40.30
-1.88 (-4.46%)
At close: Nov 5, 2026, 4:00 PM EST
40.07
-0.23 (-0.57%)
After-hours: Nov 5, 2026, 7:59 PM EST

Novo Nordisk Financials Overview

Millions DKK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Revenue
79,19578,48896,82379,14474,97676,85778,08785,68371,31168,06065,34965,86358,73154,30053,36748,09245,56641,26542,03138,333
Revenue Growth
5.63%2.12%23.99%-7.63%5.14%12.93%19.49%30.09%21.42%25.34%22.45%36.95%28.89%31.59%26.97%25.46%27.91%24.89%24.34%19.28%
Gross Profit
65,01961,38883,22564,97457,07264,01165,19773,62160,00357,78655,43356,29549,01846,44445,18539,83038,36635,19635,11432,092
Operating Income
31,72033,38959,61835,24123,68233,44938,79147,29933,82231,63431,84628,89026,91323,88825,00717,84720,18418,39119,14714,331
Net Income
16,74020,98948,55726,89120,00626,50329,03428,23027,30120,05025,40721,96322,47819,42819,81413,59214,40513,31814,21010,892
Earnings Per Share
3.794.7310.916.044.505.966.536.346.124.495.684.915.004.324.393.013.172.933.112.38
EPS Growth
-15.78%-20.61%67.07%-4.66%-26.47%32.74%14.96%29.15%22.40%3.94%29.39%63.07%57.73%47.44%41.16%26.47%20.30%11.41%14.13%18.81%

Revenue by Segment
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Ozempic Pill / Rybelsus
4,9385,2284,5725,3035,4425,6535,6956,9175,4535,9185,0135,9104,4963,9884,3564,0533,0112,1722,0631,823
Ozempic Injectable
29,70631,37527,82531,82530,74431,79932,72133,85329,80428,87527,81030,06523,91222,10119,64016,97616,39014,34912,03510,716
Victoza
1051813343995499141,1581,403-3222,2422,1591,7862,2271,8362,8153,3232,9672,7103,3223,833
Long-Acting Insulin
4,3794,4124,2324,7004,2004,4675,3885,1584,0354,7375,1653,7263,6923,3544,1333,9023,9394,1044,7964,677
Premix Insulin
2,4192,7902,3952,5092,3572,6362,8132,8672,5182,4362,9682,1232,2192,4562,7762,3432,7062,5013,0122,691
Fast-Acting Insulin
4,3794,6913,9554,8804,1094,5425,0526,0174,1503,8684,4874,1423,8083,5114,4884,4714,2633,8874,8424,520
Human Insulin
1,0881,0481,0631,3121,3271,1011,7441,8451,8061,5711,7451,9891,6261,9672,0121,9702,0531,8512,3122,085
Other Diabetes Care
531704560422421454473512492533583322594667729713798830884816
Wegovy Injectable
20,40719,48418,23521,86420,35419,52817,36019,86617,30411,6599,3779,6149,6487,5184,5632,4461,1571,1811,404782
Wegovy Pill
5,3943,2182,256-----------------
Saxenda
3454504215817528441,0641,5401,4972,2451,6581,6152,6072,7883,2793,0423,1742,4621,9981,677
Rare Blood Disorders
3,0552,8962,6333,0192,9193,0962,9213,3982,9882,8642,8882,9342,9572,8363,0492,8812,8852,8633,0772,490
Rare Endocrine Disorders
1,9941,5381,1471,8341,3931,4201,3121,9231,2277301,1131,2645429021,1281,6021,7931,9231,8201,719
Other Rare Disease
455473435496409403386384359382383373403376399370430432466504
Revenue (Total)
79,19578,48896,82379,14474,97676,85778,08785,68371,31168,06065,34965,86358,73154,30053,36748,09245,56641,26542,03138,333

Cash & Debt
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Cash & Investments
46,35244,98221,62626,96232,58318,93441,55026,30874,88162,6549,30330,23047,59536,40827,77123,57437,47331,03720,14617,485
Total Debt
134,480140,127146,382130,958101,21499,268118,723102,78756,97257,06026,92827,00626,53725,70425,51825,78425,96925,43425,48026,645
Net Cash (Debt)
-88,128-95,145-124,756-103,996-68,631-80,334-77,173-76,47917,9095,594-17,6253,22421,05810,7042,253-2,21011,5045,603-5,334-9,160
Net Cash Growth
---------14.95%-47.74%--83.05%91.04%---46.84%-58.35%--
Net Cash Per Share
-19.93-21.45-28.04-23.37-15.43-18.07-17.36-17.174.021.25-3.940.724.692.380.50-0.492.541.23-1.17-2.00

Cash Flow & CapEx
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Operating Cash Flow
41,71055,19924,0847,61946,26641,77424,73012,30143,85050,50314,3149,55140,96628,57729,8147,10124,23923,96123,586-3,017
Capital Expenditures
-13,227-12,675-11,311-18,429-13,628-14,661-13,422-16,101-12,119-10,470-8,474-9,407-5,828-5,878-4,693-4,961-3,230-2,435-1,520-2,049
Free Cash Flow
28,48342,52412,773-10,81032,63827,11311,308-3,80031,73140,0335,84014435,13822,69925,1212,14021,00921,52622,066-5,066
Free Cash Flow Growth
-12.73%56.84%12.96%-2.86%-32.27%93.63%--9.70%76.37%-76.75%-93.27%67.25%5.45%13.84%-3.33%-8.58%123.95%-

Margins
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Gross Margin
82.10%78.21%85.96%82.10%76.12%83.29%83.49%85.92%84.14%84.90%84.83%85.47%83.46%85.53%84.67%82.82%84.20%85.29%83.54%83.72%
Operating Margin
40.05%42.54%61.57%44.53%31.59%43.52%49.68%55.20%47.43%46.48%48.73%43.86%45.82%43.99%46.86%37.11%44.30%44.57%45.55%37.39%
Pretax Margin
27.06%34.24%64.21%43.19%34.03%43.98%47.43%41.50%48.22%37.22%48.84%41.94%47.78%44.67%46.35%33.93%39.57%40.70%42.63%34.21%
Profit Margin
21.14%26.74%50.15%33.98%26.68%34.48%37.18%32.95%38.28%29.46%38.88%33.35%38.27%35.78%37.13%28.26%31.61%32.27%33.81%28.41%
FCF Margin
35.97%54.18%13.19%-13.66%43.53%35.28%14.48%-4.44%44.50%58.82%8.94%0.22%59.83%41.80%47.07%4.45%46.11%52.16%52.50%-13.22%

Dividends
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Dividend Per Share
-3.750-7.950-3.750-7.900-3.500-6.400-3.000-4.075-2.125-3.450
Dividend Per Share Growth
-0%-0.63%-7.14%-23.44%-16.67%-57.05%-41.18%-18.12%-21.43%-17.95%
Dividend Yield
-3.72%-3.60%-2.65%-1.83%-0.99%-1.35%-1.29%-1.32%-1.42%-1.42%

Valuation
Chart
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingSep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
PE Ratio
9.8711.968.4014.1114.7617.5719.9327.4536.8249.6144.0537.1938.2436.6539.9538.1632.6235.3434.5235.07
P/FCF Ratio
15.3218.0516.61-22.7729.4126.31-44.8654.9661.6237.4533.8434.7234.9931.7528.9530.3527.98-
PS Ratio
3.354.233.134.684.856.266.889.5512.8917.2916.1013.4013.4312.2412.9711.9710.3111.3611.4311.90